Researchers at the Icahn School of Medicine at Mount Sinai reported that detargeting mRNA expression away from hepatocytes can strengthen T-cell immunity in preclinical lymphoma models. In Nature Biotechnology, the team found that hepatocytes can dampen vaccine potency and that redirecting expression improved immune outcomes. The study used a microRNA-based approach to silence mRNA expression in specific cell types, including dendritic cells, muscle fibers, and hepatocytes. The authors said silencing dendritic cell expression did not impair T-cell priming, while reducing expression in muscle weakened responses and hepatocyte silencing boosted them. The findings challenge a long-held assumption that strong mRNA vaccine priming requires delivering the payload to dendritic cells. Instead, the work suggests non-immune cells can significantly shape the immune response by producing antigen for handoff to the immune system. For the RNA therapeutics field, the results provide a tangible engineering target—cell-type expression patterns—for next-generation vaccine and therapeutic design.